Cargando…
Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling
AIMS/HYPOTHESIS: Diabetes is a worldwide epidemic linked with diverse diseases of the nervous system, including depression. A few studies suggested a connection between renin–angiotensin–aldosterone system blockers and reduced depressive symptoms, although underlying mechanisms are unclear. Here we...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647092/ https://www.ncbi.nlm.nih.gov/pubmed/31053872 http://dx.doi.org/10.1007/s00125-019-4888-z |
_version_ | 1783437653301002240 |
---|---|
author | Lenart, Lilla Balogh, Dora B. Lenart, Nikolett Barczi, Adrienn Hosszu, Adam Farkas, Tamas Hodrea, Judit Szabo, Attila J. Szigeti, Krisztian Denes, Adam Fekete, Andrea |
author_facet | Lenart, Lilla Balogh, Dora B. Lenart, Nikolett Barczi, Adrienn Hosszu, Adam Farkas, Tamas Hodrea, Judit Szabo, Attila J. Szigeti, Krisztian Denes, Adam Fekete, Andrea |
author_sort | Lenart, Lilla |
collection | PubMed |
description | AIMS/HYPOTHESIS: Diabetes is a worldwide epidemic linked with diverse diseases of the nervous system, including depression. A few studies suggested a connection between renin–angiotensin–aldosterone system blockers and reduced depressive symptoms, although underlying mechanisms are unclear. Here we investigated the antidepressant effect and the mechanisms of action of the angiotensin receptor 1 blocker (ARB) losartan in an experiential model of diabetes-associated depression. METHODS: Experimental diabetes was induced by streptozotocin in adult male Wistar rats. After 5 weeks of diabetes, rats were treated for 2 weeks with a non-pressor oral dose of losartan (20 mg/kg). In protocol 1, cerebrovascular perfusion and glial activation were evaluated by single-photon emission computed tomography–MRI and immunohistochemistry. In protocol 2, behaviour studies were performed (forced swim test and open field test). Hippocampal proinflammatory response and brain-derived neurotrophic factor (BDNF) signalling were also assessed. RESULTS: Here, we show that diabetic rats exhibit depression-like behaviour, which can be therapeutically reversed by losartan. This action of losartan occurs via changes in diabetes-induced neuroinflammatory responses rather than altered cerebral perfusion. We also show that as a part of its protective effect losartan restores BDNF production in astrocytes and facilitates BDNF–tropomyosin receptor kinase B–cAMP response element-binding protein signalling in the diabetic brain. CONCLUSIONS/INTERPRETATION: We identified a novel effect of losartan in the nervous system that may be implemented to alleviate symptoms of diabetes-associated depression. These findings explore a new therapeutic horizon for ARBs as possible antidepressants and suggest that BDNF could be a target of future drug development in diabetes-induced complications. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-019-4888-z) contains peer-reviewed but unedited supplementary material, which is available to authorised users. |
format | Online Article Text |
id | pubmed-6647092 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-66470922019-08-06 Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling Lenart, Lilla Balogh, Dora B. Lenart, Nikolett Barczi, Adrienn Hosszu, Adam Farkas, Tamas Hodrea, Judit Szabo, Attila J. Szigeti, Krisztian Denes, Adam Fekete, Andrea Diabetologia Article AIMS/HYPOTHESIS: Diabetes is a worldwide epidemic linked with diverse diseases of the nervous system, including depression. A few studies suggested a connection between renin–angiotensin–aldosterone system blockers and reduced depressive symptoms, although underlying mechanisms are unclear. Here we investigated the antidepressant effect and the mechanisms of action of the angiotensin receptor 1 blocker (ARB) losartan in an experiential model of diabetes-associated depression. METHODS: Experimental diabetes was induced by streptozotocin in adult male Wistar rats. After 5 weeks of diabetes, rats were treated for 2 weeks with a non-pressor oral dose of losartan (20 mg/kg). In protocol 1, cerebrovascular perfusion and glial activation were evaluated by single-photon emission computed tomography–MRI and immunohistochemistry. In protocol 2, behaviour studies were performed (forced swim test and open field test). Hippocampal proinflammatory response and brain-derived neurotrophic factor (BDNF) signalling were also assessed. RESULTS: Here, we show that diabetic rats exhibit depression-like behaviour, which can be therapeutically reversed by losartan. This action of losartan occurs via changes in diabetes-induced neuroinflammatory responses rather than altered cerebral perfusion. We also show that as a part of its protective effect losartan restores BDNF production in astrocytes and facilitates BDNF–tropomyosin receptor kinase B–cAMP response element-binding protein signalling in the diabetic brain. CONCLUSIONS/INTERPRETATION: We identified a novel effect of losartan in the nervous system that may be implemented to alleviate symptoms of diabetes-associated depression. These findings explore a new therapeutic horizon for ARBs as possible antidepressants and suggest that BDNF could be a target of future drug development in diabetes-induced complications. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00125-019-4888-z) contains peer-reviewed but unedited supplementary material, which is available to authorised users. Springer Berlin Heidelberg 2019-05-03 2019 /pmc/articles/PMC6647092/ /pubmed/31053872 http://dx.doi.org/10.1007/s00125-019-4888-z Text en © The Author(s) 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Article Lenart, Lilla Balogh, Dora B. Lenart, Nikolett Barczi, Adrienn Hosszu, Adam Farkas, Tamas Hodrea, Judit Szabo, Attila J. Szigeti, Krisztian Denes, Adam Fekete, Andrea Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling |
title | Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling |
title_full | Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling |
title_fullStr | Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling |
title_full_unstemmed | Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling |
title_short | Novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered BDNF signalling |
title_sort | novel therapeutic potential of angiotensin receptor 1 blockade in a rat model of diabetes-associated depression parallels altered bdnf signalling |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647092/ https://www.ncbi.nlm.nih.gov/pubmed/31053872 http://dx.doi.org/10.1007/s00125-019-4888-z |
work_keys_str_mv | AT lenartlilla noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling AT baloghdorab noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling AT lenartnikolett noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling AT barcziadrienn noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling AT hosszuadam noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling AT farkastamas noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling AT hodreajudit noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling AT szaboattilaj noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling AT szigetikrisztian noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling AT denesadam noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling AT feketeandrea noveltherapeuticpotentialofangiotensinreceptor1blockadeinaratmodelofdiabetesassociateddepressionparallelsalteredbdnfsignalling |